Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals director Joseph Loscalzo reported option exercises and related share sales in early March. He exercised non-qualified stock options to receive common shares at an exercise price of $38.06 per share, then sold 1,032 common shares at weighted average prices around $80–$81.
The sales, executed on March 3–4, 2026, were carried out under a pre-established Rule 10b5-1 trading plan. After these transactions, Loscalzo directly owned 36,330 common shares of Ionis Pharmaceuticals.
Ionis Pharmaceuticals director Joseph Klein III reported mixed stock transactions involving option exercises and share sales. On March 3, 2026, he exercised non-qualified stock options into 16,000 shares of common stock at exercise prices of $40.05 and $42.88 per share, then sold 21,332 shares in open-market transactions at weighted-average prices between $78.615 and $81.025, pursuant to a Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, he held 11,014 shares directly and 100 shares were reported as held indirectly by his son, for which he disclaimed beneficial ownership.
IONIS PHARMACEUTICALS INC director Allene M. Diaz reported option exercises and share sales. On March 3, 2026, she exercised non-qualified stock options covering 40,321 shares of common stock at exercise prices of $38.06, $40.05, and $41.08 per share.
On the same date, she sold a total of 54,878 shares of common stock in open-market transactions at weighted average prices ranging from about $78.57 to $81.01, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. Following these transactions, she directly held 3,811 shares of Ionis common stock.
Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, reported multiple transactions on common stock and non-qualified stock options of Ionis Pharmaceuticals Inc.
Devers exercised derivative securities and acquired common shares through option exercises, then sold 20,106 shares of common stock in open-market transactions at weighted average prices of $79.115, $79.999, and $80.837. According to the disclosure, these sales were made under a Rule 10b5-1 trading plan adopted on November 24, 2025, with individual sale prices ranging from $78.61 to $81.01. After these transactions, Devers directly owned 22,541 shares of Ionis common stock.
Ionis Pharmaceuticals executive Frank Bennett reported multiple stock transactions. On March 3, 2026, the EVP and Chief Scientific Officer exercised non-qualified stock options, receiving 16,463 common shares at an exercise price of $32.60 per share and 48,626 shares at $60.89 per share. He then sold 71,600, 12,687 and 802 common shares in open-market trades at weighted average prices of $79.099, $79.8778 and $80.762 per share, respectively, under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 80,554 Ionis common shares.
Ionis Pharmaceuticals EVP and Chief Business Officer Joseph Baroldi reported a mix of option exercises and share sales in Ionis stock. In early March 2026, he and his spouse exercised non-qualified stock options into common stock and then sold a net 6,659 shares, including 4,096 directly owned shares at $79.36 per share.
Additional indirect sales by his spouse involved smaller blocks such as 2,088 shares at $80.4079 and 36 shares at $81.01, alongside option-related acquisitions at exercise prices of $32.60 and $56.78. Footnotes state that these sales were made under Rule 10b5-1 trading plans adopted by Baroldi and his spouse.
IONS amended a Form 144 filing reporting secondary sales of common stock by Frank Bennett. The amendment lists sales of $684,264 for 8,977 shares on 01/16/2026 and $487,898 for 5,885 shares on 01/30/2026.
The filing also lists securities available to be sold including 65,089 shares tied to an option exercise (grant date 01/03/2022) and 20,000 restricted stock units (grant date 01/15/2017), as shown in the "Securities To Be Sold" section.
IONS reported a Form 144 notice proposing sales of common stock by an insider. The filing lists 8,198 shares associated with Stifel Nicolaus and shows an option‑related amount of 7,773 shares with a 03/03/2026 date. The filing also records 1,171 shares sold in the past three months by Mariana Baroldi on 03/03/2026.
Joseph Baroldi filed a Form 144 to sell Common Stock. The filing lists 4,096 shares of Common Stock tied to Restricted Stock Units (grant date 01/15/2022) and identifies Stifel Nicolaus & Company Inc. as the broker for the proposed sale dated 03/03/2026. The filing also shows recent dispositions, including sales of 5,296 shares on 01/30/2026 and 6,999 shares on 01/16/2026, with associated aggregate amounts listed in the excerpt.